

In the Claims:

Please cancel claims 52, 53 and 56 without prejudice to the filing of any divisional, continuation or continuation-in-part application.

Please amend claims 42, 46, 47, 51 and 57 to read as follows:

C1
42. (Twice Amended) An isolated recombinant human adenine nucleotide translocator polypeptide comprising an amino acid sequence that is at least 95 percent identical to a human ANT3 sequence as set forth in SEQ ID NO:33 and that localizes to a mitochondrial membrane, that is capable of binding an ANT ligand and that is produced by a method comprising culturing a host cell comprising a recombinant expression construct comprising at least one regulated promoter operably linked to a nucleic acid encoding the adenine nucleotide translocator polypeptide.

C2
46. (Twice Amended) The isolated polypeptide of claim 42 wherein the host cell lacks an endogenous human ANT1 adenine nucleotide translocator polypeptide as set forth in SEQ ID NO:31 and wherein the host cell lacks an endogenous human ANT2 adenine nucleotide translocator polypeptide as set forth in SEQ ID NO:32.

47. (Twice Amended) An isolated recombinant human adenine nucleotide translocator fusion protein comprising an adenine translocator polypeptide fused to at least one additional polypeptide sequence, wherein the ANT polypeptide comprises an amino acid sequence that is at least 95 percent identical to a human ANT3 sequence as set forth in SEQ ID NO:33 and wherein the fusion protein localizes to a mitochondrial membrane and is capable of binding an ANT ligand.

C3
51. (Twice Amended) An isolated human adenine nucleotide translocator fusion protein comprising an adenine translocator polypeptide fused to at least one additional polypeptide sequence cleavable by a protease that separates the adenine translocator polypeptide from the remainder of the fusion protein, said adenine nucleotide translocator polypeptide being capable of localizing to a mitochondrial membrane and capable of binding an ANT ligand,